Idarubicine

Colon Cancer

City of Hope Medical CenterPhase 2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 65/ 100

Competitive context

127 Active assets in the Colon Cancer cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Akeso	Phase 4	BB
Eloxatin Sun Yat-sen University	Phase 3	BB
Calcium folinate pentahydrate Akeso	Phase 3	BB
Irinotecan SCRI Development Innovations, LLC	Phase 3	BB
MACROGOLS University Medical Center Ho Chi Minh City (UMC)	Phase 4	BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

81 / 100

Acute Promyelocytic LeukemiaDormant

BBB

Indicative ·

78 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.